Case-control study | Estimation of vaccine effectiveness of CoronaVac and BNT162b2 in patients with SARS-CoV-2 Omicron

Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron – JAMA Network Open

Commentary on Twitter

The CoronaVac and BNT162b2 (Pfizer) vaccines were effective against severe outcomes due to Omicron (74-77%), but protection among older individuals in Hong Kong was more likely to wane 6 months after the second dose; boosters can bring effectiveness >90%. https://t.co/kqgwryJ1kT

— JAMA Network Open (@JAMANetworkOpen) February 3, 2023